Korro Bio, Inc. Financials
This page shows Korro Bio, Inc. (KRRO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Korro Bio, Inc. has an operating margin of -4047.1%, meaning the company retains $-4047 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Korro Bio, Inc. carries a low D/E ratio of 0.41, meaning only $0.41 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.79, Korro Bio, Inc. holds $8.79 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Korro Bio, Inc. generated -$60.1M in operating cash flow, capex of $17.9M consumed most of it, leaving -$78.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Korro Bio, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Korro Bio, Inc. generates $0.72 in operating cash flow (-$60.1M OCF vs -$83.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Korro Bio, Inc. generated $2.3M in revenue in fiscal year 2024.
Korro Bio, Inc.'s EBITDA was -$88.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 9.2% from the prior year.
Korro Bio, Inc. generated -$78.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 3.8% from the prior year.
Korro Bio, Inc. reported -$83.6M in net income in fiscal year 2024. This represents a decrease of 3.0% from the prior year.
Korro Bio, Inc. earned $-9.37 per diluted share (EPS) in fiscal year 2024. This represents an increase of 82.3% from the prior year.
Korro Bio, Inc. held $55.6M in cash against $0 in long-term debt as of fiscal year 2024.
Korro Bio, Inc. had 9M shares outstanding in fiscal year 2024. This represents an increase of 17.0% from the prior year.
Korro Bio, Inc.'s operating margin was -4047.1% in fiscal year 2024, reflecting core business profitability.
Korro Bio, Inc.'s net profit margin was -3680.4% in fiscal year 2024, showing the share of revenue converted to profit.
Korro Bio, Inc. invested $63.6M in research and development in fiscal year 2024. This represents an increase of 11.2% from the prior year.
Korro Bio, Inc. invested $17.9M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 128.5% from the prior year.
KRRO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M-25.3% | $1.5M-42.7% | $2.5M-45.8% | $4.7M | $0 | $0 | $0 | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $13.8M-34.3% | $21.0M+6.5% | $19.7M | N/A | $16.0M-6.9% | $17.1M+26.3% | $13.6M | N/A |
| SG&A Expenses | $6.5M-14.7% | $7.6M-2.6% | $7.8M | N/A | $7.3M+4.9% | $7.0M-11.3% | $7.9M | N/A |
| Operating Income | -$19.2M+29.3% | -$27.2M-8.7% | -$25.0M | N/A | -$23.3M+3.5% | -$24.1M-12.5% | -$21.5M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0-100.0% | $1K | $0 | N/A | -$9K-130.0% | $30K+76.5% | $17K | N/A |
| Net Income | -$18.1M+29.9% | -$25.8M-10.2% | -$23.4M-325.8% | -$5.5M+73.8% | -$21.0M+3.8% | -$21.8M-11.6% | -$19.6M | N/A |
| EPS (Diluted) | $-1.92+29.9% | $-2.74-10.0% | $-2.49 | N/A | $-2.26+7.0% | $-2.43+0.4% | $-2.44 | N/A |
KRRO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $161.6M-10.5% | $180.4M-10.8% | $202.2M-10.6% | $226.2M-7.1% | $243.5M-2.4% | $249.6M+26.1% | $198.0M-10.7% | $221.7M |
| Current Assets | $98.2M-4.3% | $102.6M-15.3% | $121.2M-7.8% | $131.5M-13.9% | $152.8M-6.6% | $163.6M+12.3% | $145.7M-15.7% | $172.7M |
| Cash & Equivalents | $24.2M-28.1% | $33.6M-47.6% | $64.1M+15.3% | $55.6M-12.0% | $63.2M-30.7% | $91.2M-34.3% | $138.8M-16.5% | $166.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $62.5M-4.3% | $65.3M+3.3% | $63.3M-3.9% | $65.8M+3.0% | $63.9M+24.1% | $51.5M+10.5% | $46.6M-9.9% | $51.8M |
| Current Liabilities | $14.6M-14.8% | $17.2M+33.3% | $12.9M-13.9% | $15.0M+9.9% | $13.6M+10.4% | $12.3M+11.5% | $11.1M-43.3% | $19.5M |
| Long-Term Debt | N/A | N/A | N/A | $180K-18.9% | $222K | N/A | N/A | N/A |
| Total Equity | $99.0M-14.0% | $115.1M-17.2% | $139.0M-13.4% | $160.4M-10.7% | $179.6M-9.3% | $198.1M+30.9% | $151.4M-10.9% | $169.9M |
| Retained Earnings | -$333.8M-5.7% | -$315.7M-8.9% | -$290.0M-8.8% | -$266.6M-8.6% | -$245.4M-9.4% | -$224.4M-10.8% | -$202.6M-10.7% | -$183.0M |
KRRO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.2M+10.7% | -$19.2M+21.4% | -$24.5M-226.2% | -$7.5M+53.4% | -$16.1M-10.3% | -$14.6M+33.3% | -$21.9M-3.7% | -$21.1M |
| Capital Expenditures | $175K+25.0% | $140K+17.6% | $119K-91.8% | $1.5M-70.2% | $4.9M-18.2% | $6.0M+6.2% | $5.6M+239.0% | $1.7M |
| Free Cash Flow | -$17.4M+10.4% | -$19.4M+21.2% | -$24.6M-174.6% | -$8.9M+57.3% | -$21.0M-2.0% | -$20.6M+25.3% | -$27.5M-20.8% | -$22.8M |
| Investing Cash Flow | $7.6M+167.2% | -$11.3M-134.5% | $32.8M+1285.6% | -$2.8M+78.0% | -$12.6M+87.7% | -$102.4M-1724.9% | -$5.6M-239.0% | -$1.7M |
| Financing Cash Flow | $128K+2460.0% | $5K-97.1% | $172K-81.5% | $932K+28.0% | $728K-98.9% | $67.6M+48501.4% | $139K-99.9% | $144.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
KRRO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1764.9%+98.3pp | -1863.1%-882.0pp | -981.2% | N/A | -5.2% | N/A | N/A | N/A |
| Net Margin | -1657.0%+108.1pp | -1765.1%-847.9pp | -917.1%-800.5pp | -116.7%-114.3pp | -2.4% | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -11.2%+3.1pp | -14.3%-2.7pp | -11.6%-9.1pp | -2.5%+6.2pp | -8.6%+0.1pp | -8.7%+1.1pp | -9.9% | N/A |
| Current Ratio | 6.71+0.7 | 5.98-3.4 | 9.41+0.6 | 8.79-2.4 | 11.23-2.1 | 13.28+0.1 | 13.18+4.3 | 8.87 |
| Debt-to-Equity | 0.63+0.1 | 0.57+0.1 | 0.46+0.0 | 0.41+0.1 | 0.36+0.1 | 0.26-0.0 | 0.310.0 | 0.30 |
| FCF Margin | -1592.1%-265.5pp | -1326.6%-363.0pp | -963.6%-323.0pp | -640.5%-947.6pp | 307.1% | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Korro Bio, Inc.'s annual revenue?
Korro Bio, Inc. (KRRO) reported $2.3M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Korro Bio, Inc. profitable?
No, Korro Bio, Inc. (KRRO) reported a net income of -$83.6M in fiscal year 2024, with a net profit margin of -3680.4%.
What is Korro Bio, Inc.'s earnings per share (EPS)?
Korro Bio, Inc. (KRRO) reported diluted earnings per share of $-9.37 for fiscal year 2024. This represents a 82.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Korro Bio, Inc.'s EBITDA?
Korro Bio, Inc. (KRRO) had EBITDA of -$88.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Korro Bio, Inc.'s operating margin?
Korro Bio, Inc. (KRRO) had an operating margin of -4047.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Korro Bio, Inc.'s net profit margin?
Korro Bio, Inc. (KRRO) had a net profit margin of -3680.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Korro Bio, Inc.'s free cash flow?
Korro Bio, Inc. (KRRO) generated -$78.0M in free cash flow during fiscal year 2024. This represents a -3.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Korro Bio, Inc.'s operating cash flow?
Korro Bio, Inc. (KRRO) generated -$60.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Korro Bio, Inc.'s total assets?
Korro Bio, Inc. (KRRO) had $226.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Korro Bio, Inc.'s capital expenditures?
Korro Bio, Inc. (KRRO) invested $17.9M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Korro Bio, Inc. spend on research and development?
Korro Bio, Inc. (KRRO) invested $63.6M in research and development during fiscal year 2024.
How many shares does Korro Bio, Inc. have outstanding?
Korro Bio, Inc. (KRRO) had 9M shares outstanding as of fiscal year 2024.
What is Korro Bio, Inc.'s current ratio?
Korro Bio, Inc. (KRRO) had a current ratio of 8.79 as of fiscal year 2024, which is generally considered healthy.
What is Korro Bio, Inc.'s debt-to-equity ratio?
Korro Bio, Inc. (KRRO) had a debt-to-equity ratio of 0.41 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Korro Bio, Inc.'s return on assets (ROA)?
Korro Bio, Inc. (KRRO) had a return on assets of -36.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Korro Bio, Inc.'s cash runway?
Based on fiscal year 2024 data, Korro Bio, Inc. (KRRO) had $55.6M in cash against an annual operating cash burn of $60.1M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Korro Bio, Inc.'s Piotroski F-Score?
Korro Bio, Inc. (KRRO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Korro Bio, Inc.'s earnings high quality?
Korro Bio, Inc. (KRRO) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Korro Bio, Inc.?
Korro Bio, Inc. (KRRO) scores 49 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.